• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Comment on: Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.关于《法匹拉韦治疗中重度新型冠状病毒肺炎的安全性和有效性》的评论
Int Immunopharmacol. 2022 Jan;102:107693. doi: 10.1016/j.intimp.2021.107693. Epub 2021 May 28.
2
A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.一项评估法匹拉韦和羟氯喹联合治疗中重度 COVID-19 住院成人的疗效和安全性的随机对照研究：研究方案的结构化总结。
Trials. 2020 Oct 31;21(1):904. doi: 10.1186/s13063-020-04825-x.
3
Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition.重症或危重症 SARS-CoV-2 患者使用法匹拉韦治疗的病例研究。
Int J Infect Dis. 2020 Nov;100:283-285. doi: 10.1016/j.ijid.2020.08.047. Epub 2020 Aug 21.
4
Intravenous Immunoglobulin and Favipiravir treatment for A Kidney Transplant Patient with Severe Covid-19 Pneumonia.静脉注射免疫球蛋白和法匹拉韦治疗一名患有重症新型冠状病毒肺炎的肾移植患者
Transfus Apher Sci. 2020 Dec;59(6):102904. doi: 10.1016/j.transci.2020.102904. Epub 2020 Aug 3.
5
Favipiravir and the Need for Early Ambulatory Treatment of COVID-19.法匹拉韦与COVID-19早期门诊治疗的必要性
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.02489-20.
6
Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series.口服法匹拉韦治疗严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒RNA清除延迟患者：病例系列
Crit Care. 2020 Sep 25;24(1):578. doi: 10.1186/s13054-020-03288-5.
7
Favipiravir, an antiviral for COVID-19?法匹拉韦，一种用于治疗新冠肺炎的抗病毒药物？
J Antimicrob Chemother. 2020 Jul 1;75(7):2013-2014. doi: 10.1093/jac/dkaa171.
8
Systematic Review on Repurposing Use of Favipiravir Against SARS-CoV-2.关于法匹拉韦重新用于对抗新型冠状病毒的系统评价。
Mymensingh Med J. 2020 Jul;29(3):747-754.
9
Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients.法匹拉韦治疗新型冠状病毒肺炎患者的临床疗效与安全性
J Infect. 2021 May;82(5):186-230. doi: 10.1016/j.jinf.2020.12.005. Epub 2020 Dec 7.
10
An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial.一项针对 COVID-19 感染的抗病毒药物的适应性随机安慰剂对照 II 期试验（VIRCO）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 13;21(1):847. doi: 10.1186/s13063-020-04766-5.

本文引用的文献

1
Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.法匹拉韦治疗中重度新型冠状病毒肺炎的安全性和有效性。
Int Immunopharmacol. 2021 Jun;95:107522. doi: 10.1016/j.intimp.2021.107522. Epub 2021 Mar 11.
2
A review on favipiravir: the properties, function, and usefulness to treat COVID-19.关于法匹拉韦的综述：性质、功能及在治疗 COVID-19 中的用途。
Expert Rev Anti Infect Ther. 2021 Aug;19(8):1029-1037. doi: 10.1080/14787210.2021.1866545. Epub 2020 Dec 29.
3
Therapeutic drugs for SARS-CoV-2 treatment: Current state and perspective.治疗 SARS-CoV-2 的药物：现状和展望。
Int Immunopharmacol. 2021 Jan;90:107228. doi: 10.1016/j.intimp.2020.107228. Epub 2020 Nov 27.
4
A comparative analysis for anti-viral drugs: Their efficiency against SARS-CoV-2.抗病毒药物的比较分析：它们对 SARS-CoV-2 的疗效。
Int Immunopharmacol. 2021 Jan;90:107232. doi: 10.1016/j.intimp.2020.107232. Epub 2020 Nov 30.
5
Literature-based review of the drugs used for the treatment of COVID-19.基于文献的新型冠状病毒肺炎治疗用药综述。
Curr Med Res Pract. 2020 May-Jun;10(3):100-109. doi: 10.1016/j.cmrp.2020.05.013. Epub 2020 Jun 18.
6
Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof).治疗新冠肺炎的考虑因素：对证据（或缺乏证据）的批判性回顾。
Mayo Clin Proc. 2020 Jul;95(7):1454-1466. doi: 10.1016/j.mayocp.2020.04.027. Epub 2020 Apr 30.
7
Antiviral treatment of COVID-19.COVID-19 的抗病毒治疗。
Turk J Med Sci. 2020 Apr 21;50(SI-1):611-619. doi: 10.3906/sag-2004-145.
8
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.药物治疗 2019 冠状病毒病（COVID-19）：综述。
JAMA. 2020 May 12;323(18):1824-1836. doi: 10.1001/jama.2020.6019.
9
Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection.法匹拉韦：药代动力学与对 2019 新型冠状病毒感染临床试验的关注。
Clin Pharmacol Ther. 2020 Aug;108(2):242-247. doi: 10.1002/cpt.1844. Epub 2020 Apr 21.
10
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.中国武汉严重 COVID-19 患者的临床病程和结局：一项单中心、回顾性、观察性研究。
Lancet Respir Med. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24.

Comment on: Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.

作者信息

Hashemian Seyed MohammadReza, Khoundabi Batoul, Velayati Ali Akbar

机构信息

Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Disease (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran; Chronic Respiratory Diseases Research Center (CRDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Iran Helal Institute of Applied Science and Technology, Research Center for Health Management in Mass Gathering, Red Crescent Society of the Islamic Republic of Iran, Tehran, Iran.

出版信息

Int Immunopharmacol. 2022 Jan;102:107693. doi: 10.1016/j.intimp.2021.107693. Epub 2021 May 28.

DOI:10.1016/j.intimp.2021.107693
PMID:34217670
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8162908/
Abstract
摘要